Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 938 participants.

Also called NCT06449235

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 938 participants (planned count) (from the registry)
Sponsor
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (from the registry)
Registry
  • NCT NCT06449235
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Bangladesh (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06449235. Non-randomized; no masking; primary purpose treatment. Start 2024-09 (anticipated); primary completion 2025-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh
Condition
Type2diabetes
Intervention (Drug)
Omarigliptin
Intervention (Drug)
Sulphonylureas
Intervention (Drug)
Metformin
Intervention (Drug)
Other DPP4-i
Intervention (Drug)
Thiazolidinediones
Intervention (Drug)
Alpha-Glucosidase Inhibitor
Intervention (Drug)
Glucagon-Like Peptide-1
Intervention (Drug)
Receptor Agonists (GLP1RA)
Intervention (Drug)
SGLT2 inhibitors
Lead sponsor
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (class: other)
Collaborator
Pi Research and Development Center (class: not stated)
Collaborator
Acme Laboratories Ltd. (class: not stated)

Record details

Record id
cardio:ct-nct06449235
Content hash
8fc6286e7fa0257112bfc46d700be1d22f46a48ebc100972c06e93f78e1c7c6a